Skip to main content
. 2015 Sep 20;2015:628340. doi: 10.1155/2015/628340

Figure 5.

Figure 5

Pharmacological CCR9 inhibition results in a significant improvement in colonic inflammation in mdr1a −/− mice. (a) CCX025 treatment resulted in significantly lower levels of the proinflammatory cytokines IFN-γ, IL-1β, and IL-6 in the colon; at the same time CCX025 treatment resulted in a significant elevation in the levels of the anti-inflammatory cytokine IL-10 in the colon (n = 16–19). (b) CCX025 treatment, starting at 11 weeks of age, resulted in a significant reduction in the weight-to-length ratio of the colon in mdr1a −/− mice, compared to vehicle-treated mice (n = 25). CCX025 treatment resulted in significantly reduced histological damage scores in the proximal colon (c) and the distal colon (d). All panels: ∗ P < 0.05; ∗∗ P < 0.01.